Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Upamostat

Generic Name: Upamostat

Drug Type: Small Molecule

Chemical Formula: C_₃₂H_₄₇N_₅O_₆S

CAS Number: 1191101-18-4

Unique Ingredient Identifier: S5M7KW6U17

Overview

Upamostat has been used in trials studying the treatment of Pancreatic Cancer.

Background

Upamostat has been used in trials studying the treatment of Pancreatic Cancer.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19

Phase 2

Active, not recruiting

Posted: 2023/07/20

Sponsor:

Henry M. Jackson Fou...

ID:NCT05954286

Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer

Phase 2

Completed

Posted: 2008/02/14

Sponsor:Heidelberg Pharma AG

ID:NCT00615940

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

RedHill Biopharma Secures Key Chinese Patent for COVID-19 Treatment RHB-107

a month ago

RedHill Biopharma has received allowance from China's intellectual property authority for a composition-of-matter patent covering RHB-107, strengthening its position in the $3 billion COVID-19 therapeutics market.

Upamostat Plus Gemcitabine Shows Tolerability in Advanced Pancreatic Cancer Phase I Trial

5 months ago

A phase I trial evaluating upamostat combined with gemcitabine in advanced pancreatic cancer shows manageable safety and tolerability.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy